Health Canada Approves Medicago’s Covid Vaccine

Health Canada has approved the recombinant Covid-19 vaccine produced by Canadian biotech Medicago that uses the pandemic adjuvant made by British pharma giant GlaxoSmithKline. The shot marketed as Covifenz uses a plant-based virus-like particles technology to imitate the coronavirus’ spike protein.

The approval is the first for the biotech based in Quebec City and the first for a shot using this GSK adjuvant. The technology is said to allow the vaccine to be stored at normal refrigeration temperatures of 2-8°C. The two doses are administered by intramuscular injection 21 days apart.

In a phase 3 trial with more than 24,000 adults across six countries, completed late last year, Covifenz showed 71% efficacy against several Covid variants. It was not tested against Omicron, which was not prevalent at the time of the studies.

Canada previously approved the Pfizer/BioNTech and Moderna mRNA vaccines and, most recently, the Novavax shot. In addition to those and the Medicago vaccine it has also signed a supply contract with Sanofi-GSK and several other manufacturers.

Author: Dede Williams, Freelance Journalist

(c) Medicago
(c) Medicago

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.